Abstract
Purpose
Treatment of primary prostate cancer extremely depends on preoperative stage. The role of 18F-1007-PSMA-PET/CT in preoperative staging has not been well defined. Our aim was to compare the diagnostic performance of 18F-1007-PEMA-PET/CT, mpMRI, and mpMRI + PEMA-PET/CT in local progression and lymph node invasion of prostate cancer using histopathology as the gold standard.
Materials and methods
In this retrospective study, all patients with prostate cancer who underwent mpMRI and 18F-PSMA-1007-PET/CT before operation were included. The role of preoperative imaging was evaluated by predicting the sensitivity and specificity of EPE (extraprostatic extension), SVI (seminal vesicle invasion), and lymph node invasion results.
Results
Ultimately, 130 patients were included in this study. In the preoperative judgment of EPE and SVI, mpMRI + PSMA-PET/CT had higher sensitivity and specificity. When predicting lymph node metastasis, PSMA-PET/CT was the best choice. The accuracy of mpMRI + PSMA-PET/CT and PSMA-PET/CT in the T and N stages, respectively, was affected by the least factors.
Conclusions
Based on the combined results of mpMRI and 18F-1007-PSMA-PET/CT, the accuracy of the preoperative judgment of prostatic capsule invasion can be improved, which may be conducive to developing intra-fascial technology while ensuring no tumor-touch isolation. PSMA-PET/CT has the advantages over mpMRI alone in terms of lymph node positivity. Compared with PSMA-PET/CT alone, the combined results can improve the sensitivity, but reduce specificity. Therefore, it is recommended to focus on PSMA-PET/CT to decide whether lymph node dissection should be performed.
Similar content being viewed by others
Data availability
We have uploaded an additional table to Supplementary Material, which shows all relevant statistical data.
Change history
17 May 2023
A Correction to this paper has been published: https://doi.org/10.1007/s00345-023-04431-x
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. https://doi.org/10.3322/caac.21660
Walz J, Epstein JI, Ganzer R, Graefen M, Guazzoni G, Kaouk J, Menon M, Mottrie A, Myers RP, Patel V, Tewari A, Villers A, Artibani W (2016) A critical analysis of the current knowledge of surgical anatomy of the prostate related to optimisation of cancer control and preservation of continence and erection in candidates for radical prostatectomy: an update. Eur Urol. https://doi.org/10.1016/j.eururo.2016.01.026
Hamilton ZA, Kane CJ (2016) Nerve-sparing technique during radical prostatectomy and its effect on urinary continence. Eur Urol. https://doi.org/10.1016/j.eururo.2015.08.023
de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM (2016) Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol. https://doi.org/10.1016/j.eururo.2015.07.029
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. https://doi.org/10.1016/j.eururo.2019.01.049
Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S (2019) (68)Ga-PSMA-11 PET/CT In prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml Efficacy and impact on treatment strategy. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-018-4066-4
Boreta L, Gadzinski AJ, Wu SY, Xu M, Greene K, Quanstrom K, Nguyen HG, Carroll PR, Hope TA, Feng FY (2019) Location of recurrence by gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy. Urology. https://doi.org/10.1016/j.urology.2018.12.055
Maurer T, Eiber M, Schwaiger M, Gschwend JE (2016) Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. https://doi.org/10.1038/nrurol.2016.26
Freitag MT, Kesch C, Cardinale J, Flechsig P, Floca R, Eiber M, Bonekamp D, Radtke JP, Kratochwil C, Kopka K, Hohenfellner M, Stenzinger A, Schlemmer HP, Haberkorn U, Giesel F (2018) Simultaneous whole-body (18)F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-017-3854-6
Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, Wieczorek K, Schafer M, Neels OC, Cardinale J, Kratochwil C, Hohenfellner M, Kopka K, Haberkorn U, Hadaschik BA, Giesel FL (2017) Intraindividual comparison of (18)F-PSMA-1007 PET/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective proof-of-concept study. J Nucl Med. https://doi.org/10.2967/jnumed.116.189233
Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, Mabjeesh NJ, Yossepowitch O, Mishani E, Even-Sapir E (2020) Head-to-head comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. https://doi.org/10.2967/jnumed.119.234187
Prive BM, Israel B, Schilham MGM, Muselaers CHJ, Zamecnik P, Mulders PFA, Witjes JA, Sedelaar M, Mehra N, Verzijlbergen F, Janssen MJR, Gotthardt M, Barentsz JO, van Oort IM, Nagarajah J (2021) Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-020-00292-2
Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S (2016) PI-RADS prostate imaging - reporting and data system: 2015, version 2. Eur Urol. https://doi.org/10.1016/j.eururo.2015.08.052
Kiss B, Thoeny HC, Studer UE (2016) Current status of lymph node imaging in bladder and prostate cancer. Urology. https://doi.org/10.1016/j.urology.2016.02.014
Cardinale J, Martin R, Remde Y, Schafer M, Hienzsch A, Hubner S, Zerges AM, Marx H, Hesse R, Weber K, Smits R, Hoepping A, Muller M, Neels OC, Kopka K (2017) Procedures for the GMP-compliant production and quality control of [(18)F]PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer. Pharmaceuticals (Basel). https://doi.org/10.3390/ph10040077
Krak NC, Boellaard R, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA (2005) Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-004-1566-1
Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, Govindan R, Torigian DA, Karp JS, Yu JQ, Subramaniam RM, Halvorsen RA, Siegel BA, A. R. team and M. K. R. team (2015) Repeatability of 18F-FDG PET/CT in advanced non-small cell lung cancer: prospective assessment in 2 multicenter trials. J Nucl Med. https://doi.org/10.2967/jnumed.114.147728
Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF (2018) 68Ga-PSMA-11 PET/CT in newly diagnosed prostate adenocarcinoma. Clin Nucl Med. https://doi.org/10.1097/rlu.0000000000002289
Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini IJ (2015) 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-015-3078-6
Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ (2017) (68)Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-017-3631-6
Bloch BN, Genega EM, Costa DN, Pedrosa I, Smith MP, Kressel HY, Ngo L, Sanda MG, Dewolf WC, Rofsky NM (2012) Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol. https://doi.org/10.1007/s00330-012-2475-5
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2016) The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. https://doi.org/10.1097/pas.0000000000000530
Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW, Lin DW (2017) Prostate cancer—major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. https://doi.org/10.3322/caac.21391
Funding
This research was supported by Zhejiang Provincial Natural Science Foundation of China under Grant No. LQ20H050001 and LY20H160013.
Author information
Authors and Affiliations
Contributions
YT: conceptualization, methodology, software, formal analysis, investigation, writing—original draft, visualization. XJ: methodology, formal analysis, investigation, writing—original draft. QL: conceptualization, validation, data curation, writing—review & editing, project administration. HH: validation, data curation, writing—review & editing, project administration, funding acquisition. HZ: validation, investigation. XH: validation, investigation. HX: writing—review & editing, supervision. WC: writing—review & editing, supervision, funding acquisition. YZ: conceptualization, methodology, formal analysis, investigation, writing—original draft.
Corresponding authors
Ethics declarations
Conflict of interest
The authors have nothing to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
345_2023_4345_MOESM1_ESM.tiff
Supplementary file1 T and N stage of mpMRI and PSMA-PET/CT and every patient correspongding pathological diagnosis. (A) T stage for each patients of the two methods and pathological results (each line corresponds to the same patient). (B)N stage for each patients of the two methods and pathological results (each line corresponds to the same patient) (TIFF 653 kb)
345_2023_4345_MOESM2_ESM.xlsx
Supplementary file2 a patient diagnosed with T2 and N0 stage by mpMRI. (A) T2 weighted image (T2WI) showed hypo intense signal on the peripheral zone (B) Diffusion-weighted imaging (DWI) showed a restricted diffusion (C) Apparent diffusion coefficient (ADC) showed a decreased lesion (D) An additional T2WI image which anatomically matched to Figure 1 showed no evidence of lymph node metastasis (XLSX 40 kb)
345_2023_4345_MOESM3_ESM.tif
Supplementary file3 The relationship between accuracy of different imaging diagnostic methods and patient-related information. X axis represents different imaging methods and Y axis represents different related factors. (*: p<0.05 ; **: p<0.01) (TIF 13332 kb)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Tang, Y., Ji, X., Lin, Q. et al. Status of 18F-PSMA-1007-PET/CT compared with multiparametric MRI in preoperative evaluation of prostate cancer. World J Urol 41, 1017–1024 (2023). https://doi.org/10.1007/s00345-023-04345-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-023-04345-8